Effects of glutamate-related drugs on anxiety and compulsive behavior in rats with obsessive-compulsive disorder

References

• Dryden-Edwards R, Stöppler MC. Obsessive compulsive disorder (OCD). 2016.
   Google Scholar
• Richter PM, Ramos RT. Obsessive-compulsive disorder. Continuum. 2018;24(3 Behavioral Neurology and Psychiatry):828–844.
   PubMedGoogle Scholar
• Huff W, et al. Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: Outcomes after one year. Clin Neurol Neurosurg. 2010; 112(2):137–143.
   PubMed Web of Science ®Google Scholar
• Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication. Mol Psychiatry. 2010; 15(1):53.
   PubMed Web of Science ®Google Scholar
• Ade KK, Wan Y, Hamann HC, et al. Increased metabotropic glutamate receptor 5 signaling underlies obsessive-compulsive disorder-like behavioral and striatal circuit abnormalities in mice. Biol psychiatry. 2016; 80(7):522–533.
   PubMed Web of Science ®Google Scholar
• O'Neill J, et al. Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: randomized clinical trial. Neuropsychopharmacology. 2017; 42(12):2414.
   PubMed Web of Science ®Google Scholar
• Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005; 30(9):1735–1740.
   PubMed Web of Science ®Google Scholar
• Winter C, Greene DM, Mavrogiorgou P, et al. Altered serotonergic and GABAergic neurotransmission in a mice model of obsessive-compulsive disorder. Behav Brain Res. 2018; 337:240–245.
   PubMed Web of Science ®Google Scholar
• Starck G, Ljungberg M, Nilsson M, et al. A 1 H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm. 2008; 115(7):1051.
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000; 39(9):1096–1103.
   PubMed Web of Science ®Google Scholar
• Ivarsson T, Skarphedinsson G, Kornør H, et al. The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: views based on a systematic review and meta-analysis. Psychiatry Res. 2015; 227(1):93–103.
   PubMed Web of Science ®Google Scholar
• Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014; 19(2):121–133.
   PubMed Web of Science ®Google Scholar
• Locher C, Koechlin H, Zion SR, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry. 2017; 74(10):1011–1020.
   PubMed Web of Science ®Google Scholar
• Rutrick D, Stein DJ, Subramanian G, et al. Mavoglurant in obsessive-compulsive disorder resistant to selective serotonin reuptake inhibitor: a proof-of-concept, randomized, placebo-controlled, phase 2 study. Adv Ther. 2017;34(2):524.
   PubMed Web of Science ®Google Scholar
• Alonso P, et al. Association between the NMDA glutamate receptor GRIN2B gene and obsessive–compulsive disorder. J Psychiatry Neurosci. 2012; 37(4):273.
   PubMed Web of Science ®Google Scholar
• Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry. 2006; 63(7):769.
   PubMed Web of Science ®Google Scholar
• Mataix-Cols D, Turner C, Monzani B, et al. Cognitive–behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive–compulsive disorder: pilot randomised controlled trial. Br J Psychiatry. 2014; 204(1):77–78.
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013; 47(2):175–180.
   PubMed Web of Science ®Google Scholar
• Arnold PD, Rosenberg DR, Mundo E, et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology. 2004; 174(4):530–538.
   PubMed Web of Science ®Google Scholar
• Albelda N, Joel D. Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates. Neurosci Biobehav Rev. 2012; 36(1):47–63.
   PubMed Web of Science ®Google Scholar
• Albelda N, Joel D. Current animal models of obsessive compulsive disorder: an update. Neuroscience. 2012; 211:83–106.
   PubMed Web of Science ®Google Scholar
• Alonso P, López-Solà C, Real E, et al. Animal models of obsessive–compulsive disorder: utility and limitations. Neuropsychiatr Dis Treat. 2015; 11:1939.
   PubMed Web of Science ®Google Scholar
• Egashira N, Okuno R, Harada S, et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive–compulsive disorder. Euro J Pharmacol. 2008; 586(1-3):164–170.
   PubMed Web of Science ®Google Scholar
• Szechtman H, et al. Obsessive-compulsive disorder: Insights from animal models. Neurosci Biobehav Rev. 2017; 76:254–279.
   PubMed Web of Science ®Google Scholar
• Janikova M, et al. No effect of riluzole and memantine on learning deficit following quinpirole sensitization-An animal model of obsessive-compulsive disorder. Physiol Behav. 2019; 204:241–247.
   PubMed Web of Science ®Google Scholar
• Gök Ş, Demet MM, Öztürk Z. Glutamate mGlu5 receptor antagonist, MPEP, reduces the quinpirole-induced compulsive-like checking in rats. J Obsessive-Compuls Relat Disord. 2017; 15:13–18.
   Web of Science ®Google Scholar
• Shepherd JK, Grewal SS, Fletcher A, et al. Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety. Psychopharmacology. 1994; 116(1):56–64.
   PubMed Web of Science ®Google Scholar
• Amiri S, et al. Co-occurrence of anxiety and depressive-like behaviors following adolescent social isolation in male mice; possible role of nitrergic system. Physiol Behav. 2015; 145(4):38–44.
   PubMed Web of Science ®Google Scholar
• Kulesskaya N, Voikar V. Assessment of mouse anxiety-like behavior in the light-dark box and open-field arena: role of equipment and procedure. Physiol Behav. 2014; 133(7):30–38.
   PubMed Web of Science ®Google Scholar
• Andreasen JT, Fitzpatrick CM, Larsen M, et al. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action. Brain Res. 2015; 1601:117–126.
   PubMed Web of Science ®Google Scholar
• Greeneschloesser DM, et al. Predictive validity of a non-induced mouse model of compulsive-like behavior. Behav Brain Res. 2011; 221(1):55–62.
   PubMed Web of Science ®Google Scholar
• Angoapérez M, et al. Marble burying and nestlet shredding as tests of repetitive, compulsive-like behaviors in mice. JVisualized Exp. 1940; 24(82):50978–50978.
   Google Scholar
• Matsushita M, Egashira N, Harada S, et al. Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. J Pharmacol Sci. 2005; 99(2):154–159.
   PubMed Web of Science ®Google Scholar
• Hiller A, Loeffler S, Haupt C, et al. Electrical high frequency stimulation of the caudate nucleus induces local GABA outflow in freely moving rats. J Neurosci Methods. 2007; 159(2):286–290.
   PubMed Web of Science ®Google Scholar
• Thümen A, Behnecke A, Qadri F, et al. N-methyl-norsalsolinol modulates serotonin metabolism in the rat caudate nucleus: correlation with behavioural changes. Int J Neuropsychopharm. 2003; 6(1):35–40.
   PubMed Web of Science ®Google Scholar
• Friedrichs K, Gluba S, Eidtmann H, et al. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993; 72(12):3641–3647.
   PubMed Web of Science ®Google Scholar
• Mataix-Cols D, Pertusa A, Leckman JF. Issues for DSM-V: how should obsessive-compulsive and related disorders be classified? Am J Psychiatry. 2007;164(9):1313–4.
   PubMed Web of Science ®Google Scholar
• Vorhees CV, Johnson HL, Burns LN, et al. Developmental treatment with the dopamine D2/3 agonist quinpirole selectively impairs spatial learning in the Morris water maze. Neurotoxicol Teratol. 2009; 31(1):1–10.
   PubMed Web of Science ®Google Scholar
• Mitra S, et al. Ovarian Sex hormones modulate compulsive, affective and cognitive Functions in a non-induced mouse model of obsessive-compulsive disorder. Front Behav Neurosci. 2016; 10:215.
   PubMed Web of Science ®Google Scholar
• Monteiro P, Feng G. Learning from animal models of obsessive-compulsive disorder. Biol Psychiatry. 2016; 79(1):7–16.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Berman N, Small BJ, et al. D-Cycloserine augmentation of cognitive behavior therapy for pediatric OCD: Predictors and moderators of outcome. J Affect disord. 2018; 241:454–460.
   PubMed Web of Science ®Google Scholar
• Kwon H-B, Sabatini BL. Glutamate induces de novo growth of functional spines in developing cortex. Nature. 2011; 474(7349):100.
   PubMed Web of Science ®Google Scholar
• Sun W, McConnell E, Pare J-F, et al. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. Science. 2013; 339(6116):197–200.
   PubMed Web of Science ®Google Scholar
• Spitzer S, Volbracht K, Lundgaard I, et al. Glutamate signalling: A multifaceted modulator of oligodendrocyte lineage cells in health and disease. Neuropharmacology. 2016; 110:574–585.
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, Macmillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive–compulsive disorder. Int J Neuropsychopharmacol. 2001; 4(2):179–190.
   PubMed Web of Science ®Google Scholar
• Rauch SL, Wedig MM, Wright CI, et al. Functional Magnetic Resonance Imaging Study of Regional Brain Activation During Implicit Sequence Learning in Obsessive–Compulsive Disorder. Biol Psychiatry. 2007; 61(3):330–336.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Yildirim H, Ozdemir H, et al. Hippocampus and amygdalar volumes in patients with refractory obsessive–compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008; 32(5):1283–1286.
   PubMed Web of Science ®Google Scholar
• Zhou H-X, Wollmuth LP. Advancing NMDA receptor physiology by integrating multiple approaches. Trends Neurosci. 2017; 40(3):129–137.
   PubMed Web of Science ®Google Scholar
• Goldberg JH, Yuste R, Tamas G. Ca2+ imaging of mouse neocortical interneurone dendrites: contribution of Ca2+‐permeable AMPA and NMDA receptors to subthreshold Ca2+ dynamics. J Physiol. 2003; 551(1):67–78.
   PubMed Web of Science ®Google Scholar
• Calvo-Rodríguez M, García-Durillo M, Villalobos C, et al. In vitro aging promotes endoplasmic reticulum (ER)-mitochondria Ca2+ cross talk and loss of store-operated Ca2+ entry (SOCE) in rat hippocampal neurons. Biochim Biophys Acta (BBA) Mol Cell Res. 2016; 1863(11):2637–2649.
   PubMed Web of Science ®Google Scholar
• Kash TL, Winder DG. NMDAR LTP and LTD induction: 2B or Not 2B…is that the question?. Debates Neurosci. 2007; 1(2–4):79–84.
   Google Scholar
• Papouin T, Oliet SH. Organization, control and function of extrasynaptic NMDA receptors. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1654):20130601
   PubMed Web of Science ®Google Scholar
• Tu W, Xu X, Peng L, et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell. 2010; 140(2):222–234.
   PubMed Web of Science ®Google Scholar
• Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007; 448(7156):894.
   PubMed Web of Science ®Google Scholar
• Delgado-Acevedo C, Estay SF, Radke AK, et al. Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression. Neuropsychopharmacology. 2019; 44(6):1163.
   PubMed Web of Science ®Google Scholar
• Paul S, Connor JA. NR2B‐NMDA receptor‐mediated increases in intracellular Ca2+ concentration regulate the tyrosine phosphatase, STEP, and ERK MAP kinase signaling. J Neurochem. 2010; 114(4):1107–1118.
   PubMed Web of Science ®Google Scholar
• Kanahara N, Shimizu E, Ohgake S, et al. Glycine and D-serine, but not D-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology. 2008; 198(3):363–374.
   PubMed Web of Science ®Google Scholar
• Cascella NG, Macciardi F, Cavallini C, et al. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transmission. 1994; 95(2):105–111.
   Web of Science ®Google Scholar
• Emmett M, et al. Actions of d-cycloserine at the N-methyl–aspartate-associated glycine receptor site in vivo. Neuropharmacology. 1991; 30(11):1167–1171.
   PubMed Web of Science ®Google Scholar
• Peterson SL, Schwade ND. The anticonvulsant activity of D-cycloserine is specific for tonic convulsions. Epilepsy Res. 1993; 15(2):141–148.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 1997; 17(3):141.
   PubMed Web of Science ®Google Scholar
• Pitkänen M, et al. The effects of D-cycloserine and MK-801 on the performance of rats in two spatial learning and memory tasks. Euro Neuropsychopharmacol. 1995; 5(4):457–463.
   PubMed Web of Science ®Google Scholar